二、董事会会议审议情况 1、审议通过了《关于公司2025年第三季度报告的议案》； 董事会在全面了解和审核公司 2025 年第三季度报告后一致认为：公司 2025 年第三季度报告的编制和审核程序符合法律、行政法规和中国证监会的规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。 证券代码：002826 证券简称：易明医药 公告编号：2025-065 西藏易明西雅医药科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"）第 四届董事会第二次会议于 2025 年 10 月 27 日在公司会议室以现场与通讯相结合 的方式召开。本次会议于 2025 年 10 月 17 日以电子邮件方式通知了全体董事。 本次会议应到董事 7 人，实到董事 7 人。高级管理人员列席了会议。会议 由董事长付丽华女士召集和主持，董事会秘书李前进女士出席并记录了本次会议。 本次会议的召集、召开和表决程序符合《中华人民 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥177,538,389.36, an increase of 10.37% compared to the same period last year[4] - Net profit attributable to shareholders was ¥44,206,127.26, reflecting a significant increase of 1,934.12% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,925,118.20, up by 275.79% compared to the previous year[4] - Basic earnings per share for the period was ¥0.24, representing a 2,300.00% increase year-on-year[5] - Total operating revenue for the current period was ¥488,983,972.66, a decrease of 4.3% from ¥512,843,177.87 in the previous period[29] - Operating profit increased to ¥89,326,733.14, up 74.4% from ¥51,223,379.81 in the previous period[30] - Net profit for the current period was ¥81,763,271.44, a significant increase of 92.0% compared to ¥42,620,637.91 in the previous period[30] - Basic and diluted earnings per share both rose to ¥0.44, doubling from ¥0.22 in the previous period[31] Assets and Equity - Total assets at the end of the reporting period amounted to ¥1,058,773,560.13, a growth of 14.28% from the end of the previous year[5] - Total assets increased to ¥1,058,773,560.13, up from ¥926,469,234.87, reflecting a growth of 14.2%[27] - Total equity attributable to shareholders increased to ¥802,146,877.46, marking an 8.54% rise from the previous year[5] - Total equity attributable to shareholders increased to ¥802,146,877.46 from ¥739,003,677.36, a growth of 8.5%[27] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥149,597,994.83, up by 31.41% compared to the same period last year[4] - Operating cash flow net increased by 31.41% year-on-year, driven by higher sales and government subsidies[11] - Cash inflow from operating activities totaled $600,000,709.14, a decrease of 1.6% from $611,482,717.11 in the previous period[34] - Net cash flow from operating activities increased to $149,597,994.83, up 31.5% from $113,837,202.53 in the previous period[34] - Total cash outflow from operating activities was $450,402,714.31, down from $497,645,514.58 in the previous period[34] Operating Costs and Expenses - The company's operating costs decreased by 48.35% to ¥87,288,420.68 compared to the same period last year[9] - Total operating costs decreased to ¥435,575,357.61 from ¥488,755,312.52, representing a reduction of 10.9%[29] - The company reported a significant reduction in research and development expenses to ¥9,875,884.83 from ¥12,082,095.39, a decrease of 18.3%[29] Investments and Financial Management - The company received government subsidies totaling ¥19,577,657.21 during the reporting period, contributing positively to its financial performance[6] - Investment income rose by 100.36% year-on-year, mainly attributed to increased returns from financial product investments[10] - The company reported a loss of 161.03 million yuan from its financial investments during the reporting period[22] - The company has engaged in various fixed income investments with different banks, including China Bank and Agricultural Bank, with amounts ranging from 1,000,000 to 10,000,000 yuan[22] - The expected annualized return rates for various investments range from 1.3% to 2.9%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,437[13] - The largest shareholder, Beijing Fuhai Enterprise Management Partnership, holds 23.00% of the shares[13] - Beijing Fuhai Enterprise Management Partnership holds 43,855,883 shares, accounting for 23.00% of the total shares, making it the largest shareholder[15] - The company has a total of 3,403,800 shares held in the repurchase special securities account, representing 1.79% of the total share capital[15] Changes in Management and Control - The third board of directors has been replaced, with the fourth board consisting of 3 non-independent directors and 3 independent directors[17] - The company completed the share transfer agreement on August 19, 2025, changing the controlling shareholder from Gao Fan to Beijing Fuhai[15] - The company has not reported any overdue amounts or impairment losses related to its entrusted financial management[19] - The company’s major shareholders have not participated in margin trading or securities lending activities[15] - The company has not disclosed any changes in the number of preferred shareholders or their holdings[15] - The company has not reported any significant changes in the control rights or related party transactions[15] - The company has not indicated any involvement in financing or securities lending activities among the top shareholders[15]

Group 1 - The core point of the announcement is the completion of the performance commitment compensation by the performance commitment party, Wang Jianze, to the company [1][2] - The compensation includes a cash payment of RMB 1.78 million, a distribution of after-tax dividends amounting to RMB 3,284,139.30, and a transfer of 49% equity in the target company to the company [1][2] - The company’s ownership in the target company, Inner Mongolia Bostai Enterprise Management Service Co., Ltd., increased from 51% to 100%, making it a wholly-owned subsidiary [2] Group 2 - The performance commitment party has fulfilled its obligations under the compensation agreement, including the payment of cash and the transfer of equity [2] - The company and the target company have withheld and paid the relevant taxes that should be borne by the performance commitment party [2] - The total compensation provided by the performance commitment party exceeds the fair value of the remaining equity, and the performance commitment party has compensated the company in cash for the excess amount [2]

证券代码：002826 证券简称：易明医药 公告编号：2025-064 3、剩余未补偿金额由业绩承诺方将持有标的公司的股权补偿给公司，股权 补偿比例为 18.15%； 4、由于业绩承诺方"现金+分红+股权"的补偿总额无法覆盖其应补偿额以 及公司或标的公司代扣代缴的应由业绩承诺方自行承担的税费，因此，业绩承诺 方在按协议规定执行的补偿方案之外，自愿将股权补偿后其持有的标的公司剩余 的 30.85%股权全部以零元抵偿给公司，股权补偿比例合计为 49%。 二、业绩承诺补偿的完成情况 西藏易明西雅医药科技股份有限公司 关于内蒙古博斯泰企业管理服务有限责任公司业绩承诺 方完成补偿的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、业绩承诺补偿的基本情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日在《证券时报》《中国证券报》和巨潮资讯网（www.cninfo.com.cn）上披 露了《关于公司与业绩承诺方签订<补偿协议>的公告》（公告编号：2025-054）。 根据补偿协议的规定，内蒙古博斯泰企业管理服务有限公司（以下简 ...

Core Viewpoint - The pharmaceutical sector in the Asia-Pacific market experienced a significant decline, with various indices showing notable drops, particularly in the weight loss drugs, innovative drugs, and CRO sectors [1][2]. Group 1: Market Performance - The A-share pharmaceutical and biotechnology sector saw a downturn, with weight loss drug index dropping by 1.56%, innovative drug index by 0.61%, and CRO index by 0.40% [2]. - Individual stocks such as Sunflower (向日葵) fell over 10%, while Aosaikang (奥赛康) and Guangshengtang (广生堂) also experienced significant declines of 9.02% and 6.56% respectively [3]. Group 2: Hong Kong and Japan Market Impact - The Hang Seng Biotechnology Index opened down nearly 2% and continued to decline, with companies like MicroPort Medical (微创医疗) and BeiGene (百济神州) showing notable drops of 5.47% and 4.75% respectively [4]. - In Japan, companies such as Sumitomo Pharma (住友制药) and Daiichi Sankyo (第一三共) also faced declines exceeding 4% and 3% respectively [4]. Group 3: External Factors - The recent announcement by U.S. President Trump regarding a new round of high tariffs on imported goods, including a punitive 100% tariff on patented and branded pharmaceuticals, is expected to impact the pharmaceutical industry significantly [5].

Group 1 - The chemical pharmaceutical sector experienced a decline at the beginning of trading on September 26, with Sunflower falling over 10% [1] - Aokang saw a drop of more than 8%, while other companies such as Shutaishen, Hengrui Medicine, Yiming Medicine, and Yuandong Biology also faced declines [1]

证券日报网讯易明医药（002826）9月24日在互动平台回答投资者提问时表示，截至2025年9月19日，公 司股东数为21261户。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002826 证券简称：易明医药 公告编号：2025-063 西藏易明西雅医药科技股份有限公司 关于董事会换届完成和聘任高级管理人员及其他人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于2025年9月19日召开了2025年第二次临时股 东会，选举产生了3名非独立董事和3名独立董事，与2025年5月16日召开的职工代表大会选举产生的1名 职工代表董事共同组成第四届董事会。同日，公司召开了第四届董事会第一次会议，选举产生了公司第 四届董事会董事长、董事会各专门委员会主任委员（召集人）和委员，并聘任了高级管理人员、内部审 计负责人和证券事务代表。现将具体事项公告如下： 一、第四届董事会成员组成情况 （一）董事会成员 公司第四届董事会由7名董事组成，其中非独立董事4名，独立董事3名，非独立董事中设置职工代表董 事1名。 1、非独立董事：付丽华女士（董事长）、黄凌逸女士、姚艳女士、李玲女士（职工代表董事）。 2、独立董事：何德明先生（会计专业人士 ...

Group 1 - The core point of the article is that Yiming Pharmaceutical announced the convening of its fourth board meeting and discussed the appointment of the internal audit director [1] - For the first half of 2025, Yiming Pharmaceutical's revenue composition shows that drug sales accounted for 99.71%, other revenues accounted for 0.58%, and drug promotion services accounted for -0.29% [1] - As of the report date, Yiming Pharmaceutical has a market capitalization of 3.8 billion yuan [1] Group 2 - The article also mentions that the parent company of the brand "Ancestor Bird" is facing challenges, with the new president of Greater China having been in office for just over two months and praised for his professional capabilities [1]

证券代码：002826 证券简称：易明医药 公告编号：2025-063 西藏易明西雅医药科技股份有限公司 关于董事会换届完成和聘任高级管理人员及其他人员的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开了 2025 年第二次临时股东会，选举产生了 3 名非独立董事和 3 名独立 董事，与 2025 年 5 月 16 日召开的职工代表大会选举产生的 1 名职工代表董事共 同组成第四届董事会。同日，公司召开了第四届董事会第一次会议，选举产生了 公司第四届董事会董事长、董事会各专门委员会主任委员（召集人）和委员，并 聘任了高级管理人员、内部审计负责人和证券事务代表。现将具体事项公告如下： 一、第四届董事会成员组成情况 （一）董事会成员 公司第四届董事会由 7 名董事组成，其中非独立董事 4 名，独立董事 3 名， 非独立董事中设置职工代表董事 1 名。 1、非独立董事：付丽华女士（董事长）、黄凌逸女士、姚艳女士、李玲女 士（职工代表董事）。 2、独立董事：何德明先生（会 ...